Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Amgen, Micromet to expand development of BiTE antibodies against solid tumors

Micromet, Inc. announced today that it has entered into a collaboration agreement with Amgen Inc. for the research of BiTE antibodies against three undisclosed solid tumor targets.

11 Jul 2011

NewYork-Presbyterian Hospital offers two new treatment options for cancer patients

NewYork-Presbyterian Hospital has two new treatment options for patients with brain tumors and other cancers -- a next-generation radiosurgical Gamma Knife and linear accelerator.

From Elekta 11 Jul 2011

Combination therapy shows promise against HER2-positive metastatic breast cancer

Adding Afinitor to Herceptin, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies, according to a study led by researchers at The University of Texas MD Anderson Cancer Center and published in the Journal of Clinical Oncology.

11 Jul 2011

APP receives FDA approval to market Clonidine Hydrochloride Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Clonidine Hydrochloride Injection in two dosage strengths.

11 Jul 2011

Charité-Universitätsmedizin Berlin establishes MagForce NanoTherm therapy center for treatment of tumors

Nanostart subsidiary MagForce Nanotechnologies AG, a leading medical technology company focusing on nanomedicine in oncology, announced that the Charité-Universitätsmedizin Berlin published the establishment of its NanoTherm therapy center for the treatment of recurrent brain tumors.

8 Jul 2011

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Onconova Therapeutics, Inc., and SymBio Pharmaceuticals Limited announced today that they will collaborate to develop and commercialize rigosertib in Japan and Korea. Onconova is conducting late-stage clinical trials with rigosertib (ON 01910.Na) in the U.S., Europe and India for the treatment of Myelodysplastic Syndromes (MDS) and solid tumors.

8 Jul 2011

AJMS summarizes developments related to idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a common and severe lung disease of unknown cause and with no proven therapies. But researchers are pushing forward in investigating new clues to the development and effective treatment of IPF, according to a special symposium presented in The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation (SSCI).

8 Jul 2011

Blood tests encourage more people to participate in regular screening for colorectal cancer

Epigenomics AG, the cancer molecular diagnostics company, today announced the results of a survey conducted at europacolon's first European CRC Patient Conference, The Power of Patient Voice 2011, showing that patients believe tests using blood samples would encourage more people to participate in regular screening for colorectal cancer.

8 Jul 2011

Transplants with half-matched bone marrow or cord blood are comparable to fully matched tissue

Identifying a suitable donor for leukemia and lymphoma patients who need bone marrow transplants may be far easier now that results of two clinical trials show transplant results with half-matched bone marrow or umbilical cord blood are comparable to fully matched tissue, thanks in large part to the availability of effective antirejection drugs and special post-transplant chemotherapy.

8 Jul 2011

Merck Serono announces recipients of second Grant for Fertility Innovation

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announces the recipients of its second Grant for Fertility Innovation.

8 Jul 2011

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Novartis Pharmaceuticals Corporation announced today Phase III trial results that showed more than one-third of patients taking Afinitor tablets experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas, non-cancerous brain tumors associated with tuberous sclerosis complex.

8 Jul 2011

New NCCN Clinical Practice Guideline on Malignant Pleural Mesothelioma

The National Comprehensive Cancer Network (NCCN), with the support of the NCCN Foundation, announces the latest addition to the library of NCCN Guidelines for Patients, the NCCN Guidelines for Patients: Malignant Pleural Mesothelioma.

8 Jul 2011

Roche, CPRIT partner to advance cancer research projects in Texas

The Cancer Prevention and Research Institute of Texas (CPRIT) today announced a strategic partnership agreement with the Swiss-based healthcare company Roche to accelerate the development of promising oncology-related cancer research projects in Texas.

8 Jul 2011

Medtronic enters definitive agreement to acquire Salient Surgical Technologies

Medtronic, Inc. today announced that it has entered into a definitive agreement to acquire Salient Surgical Technologies, Inc., the leader in the advanced energy category for haemostatic sealing of soft tissue and bone in a variety of surgical procedures including orthopaedic surgery, spine, open abdominal and thoracic procedures.

From Medtronic 8 Jul 2011

Medtronic enters definitive agreement to acquire PEAK Surgical

Medtronic, Inc. today announced that it has entered into a definitive agreement to acquire PEAK Surgical, Inc., a recognized leader in the emerging field of advanced energy surgical incision technology to broaden Medtronic Surgical Technologies' portfolio of innovative surgical products to meet customer and patient needs worldwide.

From Medtronic 8 Jul 2011

Half-matched transplants widen donor pool for leukemia and lymphoma

7 Jul 2011

Study finds link between genetic variation and cetuximab rectal cancer therapy

team of researchers led by Keck School of Medicine of the University of Southern California (USC) oncologist Heinz-Josef Lenz, M.D., has identified a genetic marker that may predict which patients with rectal cancer can be cured by certain chemotherapies when combined with surgery.

7 Jul 2011

Study: Cancer patients with VTE do not benefit from IVCF and fondaparinux

Cancer patients with blood clots -- which occur in one of every 200 cancer patients and are the second most common cause of death among cancer patients -- gain no benefit from the insertion of an inferior vena cava filter (IVCF) to the anticoagulant medication fondaparinux (Arixtra), according to research presented today at the 14th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer.

7 Jul 2011

Endoscopic testing prior to lung cancer surgery improves quality of life

Patients who underwent endoscopic testing prior to surgery for lung cancer had significantly better quality of life at the end of the staging process, with no significant difference in costs between the two strategies, according to data presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

7 Jul 2011

Amrubicin vs. topotecan Phase III trial against lung cancer presented at IASLC conference

Lung cancer patients given amrubicin (Calsed) as a second-line therapy had a significantly improved response rate and longer progression-free survival than patients treated with topotecan (Hycamtin), according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer.

7 Jul 2011